Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846177 | 1.00 | CYP2D6 (0.39) | CYP2D6HRH1MEN1LMNASCN1A | |
| SCHEMBL4728734 | 0.84 | POLB (0.41) | CYP2D6CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL14291856 | 0.84 | CHRM3 (0.39) | CYP2D6HRH1MEN1LMNASCN1A | |
| SCHEMBL1845152 | 0.80 | CHRM2 (0.32) | CYP2D6HRH1CHRM3CHRM2CHRM1 | |
| SCHEMBL1845153 | 0.80 | CHRM2 (0.32) | CYP2D6HRH1CHRM3CHRM2CHRM1 | |
| SCHEMBL4725504 | 0.76 | HRH1 (0.39) | CYP2D6HRH1CHRM3CHRM2CHRM1 | |
| SCHEMBL4779865 | 0.75 | CHRM2 (0.36) | CYP2D6HRH1CHRM3CYP19A1CHRM2 | |
| SCHEMBL4726237 | 0.75 | KCNH2 (0.38) | CYP2D6MEN1LMNAKMT2ACHRM3 | |
| SCHEMBL3210000 | 0.74 | CHRM3 (0.43) | CYP2D6HRH1MEN1LMNASCN1A | |
| SCHEMBL4727245 | 0.74 | CHRM2 (0.37) | CYP2D6MEN1LMNAKMT2ACHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245292-A1 | 2-HYDROXY-ETHANESULFONATE SALT | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| EP-2323653-A1 | 2-HYDROXY-ETHANESULFONATE SALT | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010019097-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018352-A1 | HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019099-A1 | 2-HYDROXY-ETHANESULFONATE SALT | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019098-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | CYP2D6 981/4885HRH1 58/4885MEN1 2642/4885 |
| US-20110245292-A1 | 2-HYDROXY-ETHANESULFONATE SALT | CHRM3, CHRM2, CHRM5 | CYP2D6 1263/4885HRH1 111/4885MEN1 4303/4885 |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | GRK5, GRK2, GRK4 | CYP2D6 1921/4885HRH1 296/4885MEN1 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.